Galectin Therapeutics Inc
GALT
Get informed when a big investor buys or sells
+ FollowMarket Cap$242.35M
Close$
$-1.82
151.6% downside
Current Fair Value
151.6% downsideOvervalued by 151.6% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $242.35 Million |
|---|---|
| Enterprise Value | $366.85 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.48 |
| Beta | 0.35 |
| Outstanding Shares | 65,875,000 |
Return
| Return on Equity | 20.35% |
|---|---|
| Return on Assets | -187.80% |
| Return on Invested Capital | -13.98% |
Valuation & Multiples
| P/E Ratio | -8.62 |
|---|---|
| PEG | -40.71 |
| Price to Sales | - |
| Price to Book Ratio | -1.17 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | 19.19 |
| Enterprise Value to Net Income | -14 |
| Total Debt to Enterprise | 0.38 |
| Debt to Equity | -1.01 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 14, 2026
EPS Estimate
$-0.09
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
November 13, 2026
EPS Estimate
$-0.10
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.1996▲ 14.38% |
|---|---|
| Total Calls | 1,138,400▼ 24.78% |
| Total Puts | 227,200▲ 169.19% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 23.94%▲ 2.85% |
|---|---|
| Total Invested | $136.48M▲ 253.92% |
| Investors Holding | 106▲ 1.00% |
ESG Score
No data
About Galectin Therapeutics Inc
CEO: Harold Shlevin